Clinical Trial

Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation

Study acronym: NINBOST2018
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study investigates the safety and tolerability of Nintedanib in patients with bronchiolitis obliterans syndrome (BOS) following allogeneic hematopoietic cell transplantation. All study patients with BOS will be treated with the study drug Nintedanib (300 mg/day) as an add-on therapy to their basic immunosuppressive treatment over a 12-months treatment period.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2019-01-14; most recent amendment 2025-12-05.
Status change: Not Yet Recruiting → Recruiting 2019-03-25
Trial Details
NCT Number NCT03805477
Lead Sponsor University Hospital, Basel, Switzerland
Conditions Bronchiolitis Obliterans Syndrome (BOS), Bronchiolitis Obliterans (BO)
Enrollment 20 participants
Start Date 2019-03-20
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-15